Immediate Hemodynamic and Clinical Results of TAVI, with the Use of a Valve with PTFE Cusps

Vladlen Bazylev, Andrey Voevodin, Evgeny Rosseykin

Federal Center of Cardiovascular surgery, Penza, Russia

Date, time and location: 2018.05.26 08:30, Congress Hall, 2F–B

Abstract

TAVI is a topic of great interest to cardio-thoracic surgeons of the world today. There are valves that have undergone trials, with good immediate and long-term results. All biological prostheses contain cusps made of biological material. 2 years ago, started clinical trial of a new valve for TAVI, the cusps of which contain PTFE.

The aim of the study was to evaluate the immediate hemodynamic and clinical results of the use of TAVI prosthesis from PTFE.

Methods. The prosthesis is a balloon expanding stent with three PTFE cusps. Pre-clinical trials were conducted, with good results. 43 TAVI operations were performed using a PTFE valve. All implantations are performed by the transapical approach. Mean age of patients was 73 ±3,6 years; female 25 (58%). All patients had a high risk of cardio surgery (EuroSCORE > 6).

Results. Evaluated the frequency of deaths, myocardial infarction, stroke, large bleeding, renal insufficiency, permanent pacemaker implantation. In addition, the mean and maximum gradient on the valve, by ultrasound.

We had 3(7%) deaths, 1 (2,3%) bleeding, 1 (2,3%) acute aorta dissection, 2 (5%) cases of a permanent pacemaker, 1 (2,3%) case of need for dialysis. There were no strokes.

A mean gradient was 5,5 mm Hg, maximum gradient 10,7 mm Hg (average values for the group).

Conclusions. The immediate results of the TAVI operation using a PTFE valve are satisfactory. Need evaluation of long term outcomes data.